2017
DOI: 10.4236/ojd.2017.62004
|View full text |Cite
|
Sign up to set email alerts
|

Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle

Abstract: Over more than 60 years, monoamine oxidase (MAO) inhibitors are available for therapy of central nervous diseases. Although they have shown to be efficacious specifically in the treatment of major depressive disorders and treatment-resistant depression, they became less a therapeutic choice for the physicians mostly due to severe side effects, such as liver failure and hypertensive crisis associated specifically with the first generation of inhibitors. Nevertheless, this class of drugs is still being used for … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
20
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 32 publications
(22 citation statements)
references
References 182 publications
2
20
0
Order By: Relevance
“…4 E). The phenotypic similarity between these drugs is consistent with the fact that MOAI inhibits serotonin metabolism resulting in its accumulation and activation of serotonin receptors in what is known as serotonin syndrome 27 , 28 . Therefore, combining phenotypic and structural similarity can facilitate the determination of the likely affected mechanism of action of a drug in a specific biological context.…”
Section: Resultssupporting
confidence: 66%
“…4 E). The phenotypic similarity between these drugs is consistent with the fact that MOAI inhibits serotonin metabolism resulting in its accumulation and activation of serotonin receptors in what is known as serotonin syndrome 27 , 28 . Therefore, combining phenotypic and structural similarity can facilitate the determination of the likely affected mechanism of action of a drug in a specific biological context.…”
Section: Resultssupporting
confidence: 66%
“…3E). The phenotypic similarity between these drugs is consistent with the fact that MOAI inhibits serotonin metabolism resulting in its accumulation and activation of serotonin receptors in what is known as serotonin syndrome (Boyer and Shannon, 2005;Entzeroth and Ratty, 2017). Therefore, combining phenotypic and structural similarity can facilitate the determination of the likely affected mechanism of action of a drug in a specific biological context.…”
Section: Identifying Multi-dimensional Phenotypic Signatures Of Endotsupporting
confidence: 53%
“…However, the X‐ray crystallographic structures of MAO‐B in complex with several small molecule inhibitors and the development of pharmacophore models for MAO‐BIs facilitated a deeper understanding of features required for inhibitor potency, and also greatly assisted in structure‐based inhibitor/drug design. Since then, much attention has been paid to the design and synthesis of potent and selective MAO‐BIs …”
Section: Development Of Pharmacophore Model For Maoismentioning
confidence: 99%